BioCentury | Oct 15, 2015
Distillery Therapeutics

Therapeutics: p53

...Phase II testing to prevent renal damage and delayed graft function (DGF) after renal transplantation. Eleos Inc....
BioCentury | Sep 30, 2010
Distillery Therapeutics

Indication: Cancer

...oligonucleotide. Next steps include developing oligonucleotides and testing them in mouse models of undisclosed diseases. Eleos Inc.'s...
BioCentury | Sep 7, 2009
Regulation

On deck in AML

...NASDAQ:CYCC)/Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) Sapacitabine (CYC682) Cell cycle modulating nucleoside analog Ph II Eleos Inc....
BioCentury | Aug 27, 2009
Targets & Mechanisms

Melanoma: eaten up inside

...whether it's better to try to induce autophagy via different routes. Larry Smith, CSO of Eleos Inc....
...melanoma models, Smith said that would suggest the complex might do better in the clinic. Eleos'...
...Haas, M.J. SciBX 2 (33); doi:10.1038/scibx.2009.1265 Published online Aug. 27, 2009 Companies and Institutions Mentioned Eleos Inc....
BioCentury | Oct 20, 2008
Clinical News

Aezea cenersen sodium regulatory update

...lymphocytic leukemia (CLL). The antisense oligonucleotide against p53 is in Phase II testing for CLL. Eleos Inc....
BioCentury | Sep 8, 2008
Company News

Anesiva management update

...San Francisco, Calif. Business: Neurology Hired: William Houghton as SVP and CMO, formerly CMO of Eleos Inc. WIR...
BioCentury | Apr 10, 2008
Distillery Therapeutics

This Week in Therapeutics

...exploring whether known tumorigenic mutations have a detectable effect on Killin function. Cleveland BioLabs Inc., Eleos Inc....
BioCentury | Jan 15, 2007
Company News

AVI BioPharma, Eleos deal

...The companies signed a cross-license agreement to develop antisense compounds targeting p53. Eleos gets an exclusive...
...to develop compounds targeting p53 to treat cancer, and AVII gets an exclusive license to Eleos'...
...indications. AVII received $500,000 up front, and both companies are eligible for milestones and royalties. Eleos'...
BioCentury | May 10, 2004
Finance

Midwest work ethic

...pilot animal studies this year for its conjugated therapeutic in catheter-associated urinary tract infections (UTIs). Eleos...
Items per page:
1 - 9 of 9
BioCentury | Oct 15, 2015
Distillery Therapeutics

Therapeutics: p53

...Phase II testing to prevent renal damage and delayed graft function (DGF) after renal transplantation. Eleos Inc....
BioCentury | Sep 30, 2010
Distillery Therapeutics

Indication: Cancer

...oligonucleotide. Next steps include developing oligonucleotides and testing them in mouse models of undisclosed diseases. Eleos Inc.'s...
BioCentury | Sep 7, 2009
Regulation

On deck in AML

...NASDAQ:CYCC)/Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) Sapacitabine (CYC682) Cell cycle modulating nucleoside analog Ph II Eleos Inc....
BioCentury | Aug 27, 2009
Targets & Mechanisms

Melanoma: eaten up inside

...whether it's better to try to induce autophagy via different routes. Larry Smith, CSO of Eleos Inc....
...melanoma models, Smith said that would suggest the complex might do better in the clinic. Eleos'...
...Haas, M.J. SciBX 2 (33); doi:10.1038/scibx.2009.1265 Published online Aug. 27, 2009 Companies and Institutions Mentioned Eleos Inc....
BioCentury | Oct 20, 2008
Clinical News

Aezea cenersen sodium regulatory update

...lymphocytic leukemia (CLL). The antisense oligonucleotide against p53 is in Phase II testing for CLL. Eleos Inc....
BioCentury | Sep 8, 2008
Company News

Anesiva management update

...San Francisco, Calif. Business: Neurology Hired: William Houghton as SVP and CMO, formerly CMO of Eleos Inc. WIR...
BioCentury | Apr 10, 2008
Distillery Therapeutics

This Week in Therapeutics

...exploring whether known tumorigenic mutations have a detectable effect on Killin function. Cleveland BioLabs Inc., Eleos Inc....
BioCentury | Jan 15, 2007
Company News

AVI BioPharma, Eleos deal

...The companies signed a cross-license agreement to develop antisense compounds targeting p53. Eleos gets an exclusive...
...to develop compounds targeting p53 to treat cancer, and AVII gets an exclusive license to Eleos'...
...indications. AVII received $500,000 up front, and both companies are eligible for milestones and royalties. Eleos'...
BioCentury | May 10, 2004
Finance

Midwest work ethic

...pilot animal studies this year for its conjugated therapeutic in catheter-associated urinary tract infections (UTIs). Eleos...
Items per page:
1 - 9 of 9